Overview

Inhibin, beta A (INHBA) is a gene that encodes a protein that functions in the negative regulation of gonadal stromal cell proliferation. The protein also exhibits tumor-suppressor activity. Missense mutations, nonsense mutations, silent mutations, frameshift deletions and insertions, and in-frame deletions and insertions are observed in cancers such as intestinal cancer, lung cancer, and skin cancer.

INHBA is altered in 1.65% of all cancers with lung adenocarcinoma, colon adenocarcinoma, cutaneous melanoma, prostate adenocarcinoma, and rectal adenocarcinoma having the greatest prevalence of alterations [3].

The most common alterations in INHBA are INHBA Mutation (1.39%), INHBA Amplification (0.28%), INHBA T135M (0.03%), INHBA E194K (0.03%), and INHBA R174H (0.03%) [3].

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.